References

1. Tupper, K. W., Wood, E., Yensen, R., & Johnson, M. W. (2015). Psychedelic medicine: a re-emerging therapeutic paradigm. Canadian Medical Association Journal, 187(14), 1054–1059. https://doi.org/10.1503/cmaj.141124
2. Shnayder, S., Ameli, R., Sinaii, N., Berger, A., & Agrawal, M. (2023). Psilocybin-assisted therapy improves psycho-social-spiritual well-being in cancer patients. Journal of Affective Disorders, 323, 592–597. https://doi.org/10.1016/j.jad.2022.11.046
3. Sloshower, J., Skosnik, P. D., Safi-Aghdam, H., Pathania, S., Syed, S., Pittman, B., & D'Souza, D. C. (2023). Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial. Journal of Psychopharmacology, 37(7), 698–706. https://doi.org/10.1177/02698811231154852
4. Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O'Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., Mletzko, T., … Griffiths, R. R. (2023). Single-dose psilocybin treatment for major depressive disorder: A randomized clinical trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530
5. Goodwin, G. M., Croal, M., Feifel, D., Kelly, J. R., Marwood, L., Mistry, S., O'Keane, V., Peck, S. K., Simmons, H., Sisa, C., Stansfield, S. C., Tsai, J., Williams, S., & Malievskaia, E. (2023). Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacology, 48(10), 1492–1499. https://doi.org/10.1038/s41386-023-01648-7
6. Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., Forbes, M., … Malievskaia, E. (2022). Single-dose psilocybin for a treatment-resistant episode of major depression. The New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443
7. Effinger, D. P., Quadir, S. G., Ramage, M. C., Cone, M. G., & Herman, M. A. (2023). Sex-specific effects of psychedelic drug exposure on central amygdala reactivity and behavioral responding. Translational Psychiatry, 13(1), 119. https://doi.org/10.1038/s41398-023-02414-5
8. Sramek, J. J., Murphy, M. F., & Cutler, N. R. (2016). Sex differences in the psychopharmacological treatment of depression. Dialogues in Clinical Neuroscience, 18(4), 447–457. https://doi.org/10.31887/DCNS.2016.18.4/ncutler
9. Gukasyan, N., & Narayan, S. K. (2024). Menstrual changes and reversal of amenorrhea induced by classic psychedelics: A case series. Journal of Psychoactive Drugs, 56(1), 50–55. https://doi.org/10.1080/02791072.2022.2157350
10. Fadiman, J., & Korb, S. (2019). Might microdosing psychedelics be safe and beneficial? An initial exploration. Journal of Psychoactive Drugs, 51(2), 118–122. https://doi.org/10.1080/02791072.2019.1593561
11. Chan, K., Rubtsova, A. A., & Clark, C. J. (2023). Exploring diagnosis and treatment of premenstrual dysphoric disorder in the U.S. healthcare system: A qualitative investigation. BMC Women's Health, 23(1), 272. https://doi.org/10.1186/s12905-023-02334-y
12. Poladian, N., Maron, A., Ghazarian, T., Fernandez-Sweeny, Y., & Nelson, A. L. (2022). Unmet needs discussed on reddit by women with premenstrual dysphoric disorder. Cyberpsychology, Behavior and Social Networking, 25(12), 810–813. https://doi.org/10.1089/cyber.2022.0072
13. Jairaj, C., & Rucker, J. J. (2022). Postpartum depression: A role for psychedelics? Journal of Psychopharmacology, 36(8), 920–931. https://doi.org/10.1177/02698811221093793